174 related articles for article (PubMed ID: 33180664)
1. A review of imlifidase in solid organ transplantation.
Lonze BE
Expert Opin Biol Ther; 2021 Feb; 21(2):135-143. PubMed ID: 33180664
[TBL] [Abstract][Full Text] [Related]
2. Imlifidase Desensitization in HLA-incompatible Kidney Transplantation: Finding the Sweet Spot.
de Weerd AE; Roelen DL; van de Wetering J; Betjes MGH; Heidt S; Reinders MEJ
Transplantation; 2024 Feb; 108(2):335-345. PubMed ID: 37340532
[TBL] [Abstract][Full Text] [Related]
3. Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.
Kjellman C; Maldonado AQ; Sjöholm K; Lonze BE; Montgomery RA; Runström A; Lorant T; Desai NM; Legendre C; Lundgren T; von Zur Mühlen B; Vo AA; Olsson H; Jordan SC
Am J Transplant; 2021 Dec; 21(12):3907-3918. PubMed ID: 34236770
[TBL] [Abstract][Full Text] [Related]
4. Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.
Huang E; Maldonado AQ; Kjellman C; Jordan SC
Am J Transplant; 2022 Mar; 22(3):691-697. PubMed ID: 34467625
[TBL] [Abstract][Full Text] [Related]
5. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody.
Lonze BE; Tatapudi VS; Weldon EP; Min ES; Ali NM; Deterville CL; Gelb BE; Benstein JA; Dagher NN; Wu M; Montgomery RA
Ann Surg; 2018 Sep; 268(3):488-496. PubMed ID: 30004918
[TBL] [Abstract][Full Text] [Related]
6. First use of imlifidase desensitization in a highly sensitized lung transplant candidate: a case report.
Roux A; Bunel V; Belousova N; Messika J; Tanaka S; Salpin M; Roussel A; Beaumont-Azuar L; Picard C; Brugiere O; Devaquet J; Sage E; Le Guen M; Taupin JL; Devriese M; Glorion M; Parquin F
Am J Transplant; 2023 Feb; 23(2):294-297. PubMed ID: 36695676
[TBL] [Abstract][Full Text] [Related]
7. Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes).
Jordan SC; Legendre C; Desai NM; Lorant T; Bengtsson M; Lonze BE; Vo AA; Runström A; Laxmyr L; Sjöholm K; Schiött Å; Sonesson E; Wood K; Winstedt L; Kjellman C; Montgomery RA
Transplantation; 2021 Aug; 105(8):1808-1817. PubMed ID: 33093408
[TBL] [Abstract][Full Text] [Related]
8. Imlifidase therapy: exploring its clinical uses.
Rostaing L; Noble J; Malvezzi P; Jouve T
Expert Opin Pharmacother; 2023 Feb; 24(2):259-265. PubMed ID: 36404277
[TBL] [Abstract][Full Text] [Related]
9. Advances in desensitization for human leukocyte antigen incompatible kidney transplantation.
Vo A; Ammerman N; Jordan SC
Curr Opin Organ Transplant; 2024 Apr; 29(2):104-120. PubMed ID: 38088373
[TBL] [Abstract][Full Text] [Related]
10. [Kidney Transplant in a Highly Sensitized Patient Treated with Imlifidase].
D'Elia L; Cencioni L; Ciabattini F; D'Argenzio L; Santirosi PV
G Ital Nefrol; 2023 Oct; 40(5):. PubMed ID: 38010248
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
[TBL] [Abstract][Full Text] [Related]
12. Imlifidase in kidney transplantation.
Kanbay M; Copur S; Guldan M; Topcu AU; Ozbek L; Hasbal B; Süsal C; Kocak B; Callemeyn J; Segelmark M
Clin Kidney J; 2024 Mar; 17(3):sfae033. PubMed ID: 38504664
[TBL] [Abstract][Full Text] [Related]
13. Highly Sensitized Patients Are Well Served by Receiving a Compatible Organ Offer Based on Acceptable Mismatches.
Heidt S; Haasnoot GW; van der Linden-van Oevelen MJH; Claas FHJ
Front Immunol; 2021; 12():687254. PubMed ID: 34248971
[TBL] [Abstract][Full Text] [Related]
14. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
Malvezzi P; Jouve T; Noble J; Rostaing L
Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
[TBL] [Abstract][Full Text] [Related]
15. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
[TBL] [Abstract][Full Text] [Related]
16. HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers.
Joher N; Matignon M; Grimbert P
Front Immunol; 2021; 12():688301. PubMed ID: 34093594
[TBL] [Abstract][Full Text] [Related]
17. Imlifidase-generated Single-cleaved IgG: Implications for Transplantation.
Bockermann R; Järnum S; Runström A; Lorant T; Winstedt L; Palmqvist N; Kjellman C
Transplantation; 2022 Jul; 106(7):1485-1496. PubMed ID: 34966107
[TBL] [Abstract][Full Text] [Related]
18. Imlifidase: First Approval.
Al-Salama ZT
Drugs; 2020 Nov; 80(17):1859-1864. PubMed ID: 33058042
[TBL] [Abstract][Full Text] [Related]
19. Desensitization Protocol in Recipients of Deceased Kidney Donor With Donor-Specific Antibody-Low Titers.
Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Avila Bernabeu A; Crespo Albiach J; Molina Vila P; Beltrán Catalan S; Pallardó Mateu L
Transplant Proc; 2016 Nov; 48(9):2880-2883. PubMed ID: 27932097
[TBL] [Abstract][Full Text] [Related]
20. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
